Silverback Therapeutics announces final exchange ratio of 1.1819 for merger with ARS Pharma

ARS Pharmaceuticals, Inc.

Final exchange ratio set at 1.1819 per the Merger Agreement as amended on October 25, 2022.
Merger with ARS Pharmaceuticals remains subject to stockholder approval and other closing conditions.
Shareholders are urged to read the definitive proxy statement filed on October 6, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.